{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:30:47Z","timestamp":1793982647284,"version":"4.8.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001774","name":"New Jersey Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007489","name":"Bausch and Lomb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","canadianjournalofophthalmology.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jcjo.2023.05.009","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T19:46:46Z","timestamp":1685994406000},"page":"247-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of netarsudil 0.02% in lowering intraocular pressure in patients with secondary glaucoma"],"prefix":"10.1016","volume":"59","author":[{"given":"Marko","family":"Oydanich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H.","family":"Roll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri","family":"Uppuluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert S.","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2023.05.009_bib0001","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1093\/hmg\/ddx184","article-title":"Genetics of glaucoma","volume":"26","author":"Wiggs","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jcjo.2023.05.009_bib0002","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","article-title":"Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study","volume":"204","author":"Khouri","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.05.009_bib0003","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.05.009_bib0004","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00417-019-04283-5","article-title":"Rho kinase inhibitors\u2014a review on the physiology and clinical use in Ophthalmology","volume":"257","author":"Moura-Coelho","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.05.009_bib0005","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00417-018-3933-9","article-title":"Efficacy and safety of ripasudil, a rho-associated kinase inhibitor, in eyes with uveitic glaucoma","volume":"256","author":"Kusuhara","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.05.009_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-66928-4","article-title":"Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study","volume":"10","author":"Futakuchi","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjo.2023.05.009_bib0007","doi-asserted-by":"crossref","first-page":"e807","DOI":"10.1097\/IJG.0000000000000508","article-title":"Efficacy of topically administered rho-kinase inhibitor AR-12286 in patients with exfoliation syndrome and ocular hypertension or glaucoma","volume":"25","author":"Skaat","year":"2016","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jcjo.2023.05.009_bib0008","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ogla.2020.10.005","article-title":"Early experience with netarsudil in pediatric patients: a retrospective case series","volume":"4","author":"Rapuano","year":"2021","journal-title":"Ophthalmol Glaucoma"},{"key":"10.1016\/j.jcjo.2023.05.009_bib0009","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajo.2021.01.019","article-title":"Netarsudil improves trabecular outflow facility in patients with primary open angle glaucoma or ocular hypertension: a phase 2 study","volume":"226","author":"Sit","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.05.009_bib0010","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/IJG.0000000000001634","article-title":"Pooled efficacy and safety profile of netarsudil ophthalmic solution 0.02% in patients with open-angle glaucoma or ocular hypertension","volume":"29","author":"Singh","year":"2020","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jcjo.2023.05.009_bib0011","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.2147\/OPTH.S318897","article-title":"Ripasudil endgame: role of rho-kinase inhibitor as a last-ditch-stand towards maximally tolerated medical therapy to a patient of advanced glaucoma","volume":"15","author":"Naik","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.05.009_bib0012","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1089\/jop.2019.0089","article-title":"One-year efficacy and safety assessment of ripasudil, a rho kinase inhibitor, in an addition to or replacing existing treatment regimens: a retrospective study","volume":"36","author":"Tsukahara","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jcjo.2023.05.009_bib0013","first-page":"83","article-title":"Intraocular pressure-lowering effect of ripasudil hydrochloride hydrate and reasons for discontinuation of use in clinical practice","volume":"5","author":"Kawara","year":"2018","journal-title":"Int. J Ophthalmol Clin Res."},{"key":"10.1016\/j.jcjo.2023.05.009_bib0014","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1007\/s12325-016-0389-3","article-title":"Additive intraocular pressure lowering effects of the rho kinase inhibitor, ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy","volume":"33","author":"Sato","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.jcjo.2023.05.009_bib0015","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","article-title":"Phase 2 randomized clinical study of a rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension","volume":"156","author":"Tanihara","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.05.009_bib0016","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ajo.2020.09.050","article-title":"Randomized, double-masked trial of netarsudil 0.02% ophthalmic solution for prevention of corticosteroid-induced ocular hypertension","volume":"222","author":"Price","year":"2021","journal-title":"Am J Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418223001680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418223001680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T16:12:13Z","timestamp":1729008733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418223001680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0008418223001680"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2023.05.009","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of netarsudil 0.02% in lowering intraocular pressure in patients with secondary glaucoma","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2023.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}